Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in
combination with dexamethasone in participants with t(11;14) positive relapsed (comes back)
or refractory (did not get better) light chain amyloidosis.